ACS medicinal chemistry letters

New Developments in Psychedelic Treatments: Modified Iboga Compounds, Brainwave-Guided Psilocybin Dosing, and Improved Harmine-DMT Combinations

Updated

Abstract

Recent innovations include simplified iboga analogs and real-time EEG biomarkers for individualized psilocybin dosing.

  • Simplified iboga analogs may offer tunable polypharmacology.
  • Real-time EEG biomarkers could help tailor psilocybin dosing to individual needs.
  • Standardized harmine-DMT ratios are associated with high bioavailability.
  • These advancements may contribute to the development of safer and more reliable psychedelic medicines.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free